EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CC Chemokine 2 Promotes Ovarian Cancer Progression through the MEK/ERK/MAP3K19 Signaling Pathway

Wei Liu, Lei Wang, Jiajia Zhang, Kun Cheng, Wenming Zheng iD, Zhenling Ma iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms241310652 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Wei Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Life Sciences, Henan Agricultural University, Zhengzhou 450002, China. Hauptthemen laut MEDLINE: Genital Neoplasms, Female, Ovarian Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Henan Province, Key Scientific Research Project of Henan Province, Research Start-Up Fund to Topnotch Talents of Henan Agricultural University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ovarian cancer is a gynecological tumor with an incidence rate lower than those of other gynecological tumor types and the second-highest death rate. CC chemokine 2 (CCL2) is a multifunctional factor associated with the progression of numerous cancers. However, the effect of CCL2 on ovarian cancer progression is unclear. Here, we found that exogenous CCL2 and the overexpression of CCL2 promoted the proliferation and metastasis of ovarian cancer cells. On the other hand, CCL2 knockdown via CRISPR/Cas9 inhibited ovarian cancer cell proliferation, migration, and invasion. The present study demonstrated that mitogen-activated protein three kinase 19 (MAP3K19) was the key CCL2 target for regulating ovarian cancer progression through transcriptome sequencing. Additionally, MAP3K19 knockout inhibited ovarian cancer cell proliferation, migration, and invasion. Furthermore, CCL2 increased MAP3K19 expression by activating the mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway. The present study showed the correlation between CCL2 and ovarian cancer, suggesting that CCL2 may be a novel target for ovarian cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genital Neoplasms, FemaleOvarian NeoplasmsHumansFemaleExtracellular Signal-Regulated MAP KinasesMitogen-Activated Protein Kinase KinasesMitogensMAP Kinase Signaling SystemChemokine CCL2Signal TransductionChemokinesCell Line, TumorMAP Kinase Kinase Kinases

Stichwörter der Autor:innen

CC-chemokine ligand 2MAPK/ERK pathwaymitogen-activated protein three kinase 19ovarian cancertumor progression

Substanzen

Extracellular Signal-Regulated MAP KinasesMitogen-Activated Protein Kinase KinasesMitogensChemokine CCL2ChemokinesMAP3K19 protein, humanMAP Kinase Kinase Kinases

Autor:innen und Institutionen

  • College of Life Sciences, Henan Agricultural University, Zhengzhou 450002, China.

ORCID-Profile: Wenming Zheng, Zhenling Ma

Förderung

  • Natural Science Foundation of Henan Province
  • Key Scientific Research Project of Henan Province
  • Research Start-Up Fund to Topnotch Talents of Henan Agricultural University

Zitieren

APA

Liu, W., Wang, L., Zhang, J., Cheng, K., Zheng, W., & Ma, Z. (2023). CC Chemokine 2 Promotes Ovarian Cancer Progression through the MEK/ERK/MAP3K19 Signaling Pathway. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241310652

Vancouver

Liu W, Wang L, Zhang J, Cheng K, Zheng W, Ma Z. CC Chemokine 2 Promotes Ovarian Cancer Progression through the MEK/ERK/MAP3K19 Signaling Pathway. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241310652

BibTeX
@article{Liu2023,
  author = {Liu, Wei and Wang, Lei and Zhang, Jiajia and Cheng, Kun and Zheng, Wenming and Ma, Zhenling},
  title = {CC Chemokine 2 Promotes Ovarian Cancer Progression through the MEK/ERK/MAP3K19 Signaling Pathway},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms241310652}
}
Kostenlos starten →